159 related articles for article (PubMed ID: 18476791)
1. A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
Shah SR
Expert Opin Biol Ther; 2008 Jun; 8(6):799-804. PubMed ID: 18476791
[TBL] [Abstract][Full Text] [Related]
2. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
[TBL] [Abstract][Full Text] [Related]
3. Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.
Blažek B; Misbah SA; Soler-Palacin P; McCoy B; Leibl H; Engl W; Empson V; Gelmont D; Nikolov N
Immunotherapy; 2015; 7(7):753-63. PubMed ID: 25865232
[TBL] [Abstract][Full Text] [Related]
4. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
Bussel JB; Eldor A; Kelton JG; Varon D; Brenner B; Gillis S; Angiolillo A; Kulkarni R; Abshire TC; Kelleher J;
Thromb Haemost; 2004 Apr; 91(4):771-8. PubMed ID: 15045139
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
[TBL] [Abstract][Full Text] [Related]
7. The product: All intravenous immunoglobulins are not equivalent.
Siegel J
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):78S-84S. PubMed ID: 16229678
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study.
Bresee JS; Mast EE; Coleman PJ; Baron MJ; Schonberger LB; Alter MJ; Jonas MM; Yu MY; Renzi PM; Schneider LC
JAMA; 1996 Nov; 276(19):1563-7. PubMed ID: 8918853
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.
Roifman CM; Schroeder H; Berger M; Sorensen R; Ballow M; Buckley RH; Gewurz A; Korenblat P; Sussman G; Lemm G
Int Immunopharmacol; 2003 Sep; 3(9):1325-33. PubMed ID: 12890430
[TBL] [Abstract][Full Text] [Related]
10. The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.
Mahadevia PJ
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):94S-100S. PubMed ID: 16229680
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
Ballow M; Berger M; Bonilla FA; Buckley RH; Cunningham-Rundles CH; Fireman P; Kaliner M; Ochs HD; Skoda-Smith S; Sweetser MT; Taki H; Lathia C
Vox Sang; 2003 Apr; 84(3):202-10. PubMed ID: 12670369
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
[TBL] [Abstract][Full Text] [Related]
13. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
[No Abstract] [Full Text] [Related]
14. Safety of IGIV therapy and infusion-related adverse events.
Ballow M
Immunol Res; 2007; 38(1-3):122-32. PubMed ID: 17917017
[TBL] [Abstract][Full Text] [Related]
15. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins.
Stein MR
Postgrad Med; 2010 Sep; 122(5):176-84. PubMed ID: 20861601
[TBL] [Abstract][Full Text] [Related]
16. Pharmacy considerations for the use of IGIV therapy.
Shah S
Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S5-11. PubMed ID: 16100386
[TBL] [Abstract][Full Text] [Related]
17. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
18. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
Pirofsky B
Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
Bussel JB; Hanna K;
Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
[TBL] [Abstract][Full Text] [Related]
20. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.
Schiff RI; Williams LW; Nelson RP; Buckley RH; Burks W; Good RA
J Clin Immunol; 1997 Jan; 17(1):21-8. PubMed ID: 9049782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
